Increasing the likelihood of biosimilar success with chemistry, manufacturing and control

There have been 18 biosimilars approved by the FDA through the 351(k) pathway as of the end of March 2019. Though this demonstrates the strength of the biosimilars market, there are also hurdles that prevent a number of biosimilars from reaching their intended targets.